US biotech, Visterra, has joined hands with vaccine giant, Serum Institute of India, to take its early stage monoclonal antibody product candidate (VIS513) for dengue forward.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?